New Delhi: The Centre on Saturday allowed the usage of low-cost steroid drug ‘Dexamethasone’ to treat the patients of COVID-19 with moderate and severe symptoms. The drug has been approved to be used in place of methylprednisolone, which was used earlier in treating COVID patients.
The approval from the government came after the World Health Organisation urged the countries to increase the production of dexamethasone. The Union Health Ministry updated the “Clinical Management Protocol: COVID-19” document, which was published to be used by health care officials in treating COVID patients.
According to the “Clinical Management Protocol: COVID-19” document, dexamethasone can be used on the COVID patients who are on oxygen support and on those who have an excessive inflammatory response.
Earlier this month, two researchers in the United Kingdom had found this low-cost steroid ‘Dexamethasone’ which had proved to be helpful in treating critical COVID-19 patients dependent on ventilators or oxygen supply.
However, researchers at that time said that the findings are still in the preliminary stage. The researchers also suggest that the drug should immediately become standard care in patients treated in the hospital with the pandemic disease.
Now the World Health Organisation (WHO) has emphasised on the usage of dexamethasone for critical COVID patients under close clinical supervision.
On Thursday, Hyderabad-based drugmaker Hetero, which has the approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, sent 20,000 vials to five states including Maharashtra and Delhi – the two worst-affected states in the country.
India has crossed the grim milestone of 5 lakh cases today, 6 days after crossing the3 lakh-mark. With highest single-day jump of 18,552 cases, the total number of coronavirus cases in the country reached 5,08,953, while the death toll also reached 15,685 after 384 deaths in the last 24 hours.